Zimbabwe is now one of the first countries in the world to start a lenacapavir program, which was made possible through funding from the United States government and The Global Fund.

An ongoing phase 2 trial (NCT07222579) has seen early success with a new subcutaneous formulation of blinatumomab (Blincyto) in a patient with CD19-positive mixed phenotype acute leukemia (MPAL), a ...

Researchers evaluated the association between the use of various hormonal contraceptives and the risk for surgically treated intracranial meningioma.

Zimbabwe is one of the first countries to introduce the HIV prevention drug lenacapavir. The program aims to target over 46,000 high-risk individuals, backed by U.S. funding and the Global Fund.

Zimbabwe's health authorities on Thursday began administering the long-acting HIV prevention drug lenacapavir, making the country one of the first globally to roll it out as the southern African ...

The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.

Halozyme Therapeutics is entering a powerful earnings inflection. FY25 revenue grew 38% to $1.397 billion. Check out why I am bullish on HALO stock.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript February 17, 2026 Halozyme Therapeutics, Inc.

In the heart of Mississippi, Diana "Di" Fillhart, a vibrant 68-year-old, lives a life defined by purpose and an unwavering ...

Current quarter guidance for 2026 total revenue of $1.71 billion to $1.81 billion and non-GAAP diluted EPS of $7.75 to $8.25 marks a substantial increase from the previous quarter's guidance of $1.3 ...

Dr. Ashkan Emadi, principal investigator of a first-in-world phase 2 clinical trial evaluating subcutaneous Blincyto (blinatumomab) for CD19-positive mixed phenotype acute leukemia, sat down for an ...

The agency last December approved subcutaneous Rybrevant on a biweekly dosing schedule across all of its indications.